What do systematic reviews say?

Rituximab vs intravenous methylprednisolone

Summary of findings table ‐ Rituximab showed no clear difference in CAS improvement (decrease) by 2 or more points compared with intravenous methylprednisolone (low certainty).

• Rituximab for thyroid‐associated ophthalmopathy 2022 · Cochrane Headline outcomes only
  RR 1.32 [0.98, 1.78]
  1 study · 31 participants
  Low

Rituximab vs intravenous methylprednisolone

It is very uncertain whether summary of findings table ‐ Rituximab changes NOSPECS improvement (decrease) by 2 or more classes compared with intravenous methylprednisolone (very low certainty).

• Rituximab for thyroid‐associated ophthalmopathy 2022 · Cochrane Headline outcomes only
  RR 1.07 [0.25, 4.49]
  1 study · 31 participants
  Very low

Rituximab vs intravenous methylprednisolone

It is very uncertain whether summary of findings table ‐ Rituximab changes proptosis improvement (decrease) by 2 mm or more compared with intravenous methylprednisolone (very low certainty).

• Rituximab for thyroid‐associated ophthalmopathy 2022 · Cochrane Headline outcomes only
  RR 0.35 [0.02, 8.08]
  1 study · 31 participants
  Very low

Rituximab vs intravenous methylprednisolone

It is very uncertain whether summary of findings table ‐ Rituximab changes palpebral aperture improvement (decrease) by 3 mm or more compared with intravenous methylprednisolone (very low certainty).

• Rituximab for thyroid‐associated ophthalmopathy 2022 · Cochrane Headline outcomes only
  RR 5.31 [0.28, 102.38]
  1 study · 31 participants
  Very low

Rituximab vs intravenous methylprednisolone

It is very uncertain whether summary of findings table ‐ Rituximab changes motility improvement (increase) by 1 class or more compared with intravenous methylprednisolone (very low certainty).

• Rituximab for thyroid‐associated ophthalmopathy 2022 · Cochrane Headline outcomes only
  RR 1.07 [0.25, 4.49]
  1 study · 31 participants
  Very low

Rituximab vs intravenous methylprednisolone

• Rituximab for thyroid‐associated ophthalmopathy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 27 participants
  Very low

Rituximab vs intravenous methylprednisolone

Summary of findings table ‐ Rituximab showed no clear difference in adverse events compared with intravenous methylprednisolone (low certainty).

• Rituximab for thyroid‐associated ophthalmopathy 2022 · Cochrane Headline outcomes only
  RR 1.39 [0.9, 2.13]
  1 study · 31 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• Laser peripheral iridoplasty for chronic angle closure 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Laser peripheral iridoplasty for chronic angle closure 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Laser peripheral iridoplasty for chronic angle closure 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Laser peripheral iridoplasty for chronic angle closure 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Laser peripheral iridoplasty for chronic angle closure 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Very low

Intervention not reported

• Laser peripheral iridoplasty for chronic angle closure 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 80 participants
  Low

Intervention not reported

• Laser peripheral iridoplasty for chronic angle closure 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 80 participants
  Low

Intervention not reported

• Laser peripheral iridoplasty for chronic angle closure 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 80 participants
  Low

Intervention not reported

• Laser peripheral iridoplasty for chronic angle closure 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 80 participants
  Low

Intervention not reported

• Laser peripheral iridoplasty for chronic angle closure 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 80 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• Laser peripheral iridoplasty for chronic angle closure 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Laser peripheral iridoplasty for chronic angle closure 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 80 participants
  Very low

Intervention not reported

The review found no eligible studies for this question.

• Laser peripheral iridoplasty for chronic angle closure 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found